Insmed Incorporated, a biopharmaceutical company, engages in the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders in the United States. Its lead product includes IPLEX, mecasermin rinfabate injection, which is used for the treatment of growth failure in children with primary IGF-1 deficiency. The company’s IPLEX is also in Phase II clinical trials for the treatments of myotonic muscular dystrophy; HIV associated adipose redistribution syndrome; and extreme insulin resistance. Its other products in pipeline include INSM-18, a Phase I/II clinical trial product, which would be used for the treatment of refractory prostate...